Collegium enters Phase III with DETERx oxycodone
This article was originally published in Scrip
Collegium Pharmaceuticals, the private US company, is taking its lead product, a novel formulation of oxycodone, into a Phase III trial for chronic pain. The double-blind parallel group study will compare COL-003 with placebo over 12 weeks in patients with moderate-to-severe chronic lower back pain.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.